Sprint Bioscience AB (publ) has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals Inc. The total potential value of the agreement amounts to USD 316 million plus single-digit royalties on sales of a future drug from the program. Upon entering into the agreement, Sprint Bioscience will receive an upfront payment of USD 3 million. In addition, Sprint Bioscience will project-lead the program and be reimbursed for continuing preclinical research and development activities in the coming two years.

In addition to the upfront payment and research funding, Sprint Bioscience is entitled to payments linked to predefined milestones during the program's continued development, its regulatory process, and commercialization of a potential drug. The total value of these payments is up to USD 313 million.